Comparison 3. Long‐term antiplatelet therapy (start versus avoid).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 All major adverse cardiovascular events (MACE)	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.64, 1.22]
3.2 Death	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	1.08 [0.76, 1.53]
3.3 Ischaemic stroke	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	0.70 [0.40, 1.23]
3.4 Myocardial infarction	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.21, 1.89]
3.5 All major occlusive vascular events	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.68, 1.55]
3.6 Intracerebral haemorrhage	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	0.52 [0.27, 1.03]
3.7 Major extracerebral haemorrhage	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	2.67 [0.72, 9.94]
3.8 Vascular death	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.38, 1.18]
3.9 Functional status (modified Rankin Scale score 0‐2) at 1 year	1	461	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.77, 1.18]
3.10 Deep vein thrombosis	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	3.00 [0.61, 14.73]
3.11 All major haemorrhagic events	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	0.72 [0.40, 1.29]
3.12 Major vascular events as defined by the Antithrombotic Trialists’ Collaboration	1	536	Risk Ratio (M‐H, Fixed, 95% CI)	0.69 [0.49, 0.97]